Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
← catalyst calendarNCT07721025 · readout ≤ 2,141 d
Sponsored by Lexeo Therapeutics (industry) · LXEO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
26estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-25 | actual | When the study began enrolling |
| Primary completion | Jun 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Friedreich Ataxia
- Cardiomyopathy, Secondary
Interventions
- Genetic: LX2006
- Other: Usual Care
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in left ventricular mass index by cardiac MRI
measured At Week 26
Permalink · LXEO's whole pipeline · Catalyst calendar · Every registered study · What changed